DOPPS Practice Monitor to DOPPS.org
 
Last Data Update:  May 2021 (data through February 2021)
Featured Data
Browse All Data
News & Publications
About DPM-HD
 Download Quality of Life Data
1.  Filter By:    
2.  Choose a category:


3.  Browse graphics:
Skip Navigation Links.
Expand Anemia<input id='gid' type=hidden class='gidclass' value=''><input id='c' type=hidden class='cclass1p' value='1p'><input id='p' type=hidden class='pclass' value=''>Anemia
Click to Enlarge

Sample sizes and statistics for figure above   -   Understanding the DPM Figures   -   Share

Sample sizes and statistics for figure above   -   Understanding the DPM Figures

  

SHARE





  

Copyright © 2023, Arbor Research Collaborative for Health.  |   |  Privacy Policy  |  Feedback?
Sign up here to receive communications from DOPPS
DOPPS Practice Monitor

  • Featured Data
  • Browse All Data
  • News and Publications
  • About DPM
  • Demographics
    • Age, categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Age, continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Time on dialysis, categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
    • Time on dialysis, continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
    • Gender
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Race
      • National sample
      • Hospital-based/Free-standing
      • Incident (<90d)/prevalent (90+d)
    • Ethnicity
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Body-mass index, categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Body-mass index, continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
  • Diabetes/Cardiovascular
    • Diabetes as cause of ESRD
      • National sample
    • Diabetes at study entry
      • National sample
    • HbA1c (most recent)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • HbA1c (3 month average)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • HbA1c measurement
      • Measurement in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Pre-dialysis systolic blood pressure, categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Pre-dialysis systolic blood pressure, continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Aspirin use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Beta blocker use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Calcium channel blocker use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • RAAS inhibitor use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • RAAS inhibitor use, by type
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Statin use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Ezetimibe use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • LDL cholesterol (most recent), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • LDL cholesterol (most recent), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • HDL cholesterol (most recent), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • HDL cholesterol (most recent), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Triglycerides (most recent), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Triglycerides (most recent), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Total cholesterol (most recent), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Total cholesterol (most recent), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
  • Anemia
    • Hemoglobin (most recent)
      • All patients, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • All patients, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Hemoglobin (3 month average)
      • All patients, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • All patients, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Erythropoiesis Stimulating Agent (ESA) use
      • Use in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Route of administration
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • ESA type
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Weekly IV epoetin dose received
      • 30 day average, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 30 day average, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • IV iron use
      • Use in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • IV iron type
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Monthly IV iron dose received
      • 30 day average, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 30 day average, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum ferritin (most recent)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum ferritin (3 month average)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Ferritin measurement
      • Measurement in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Transferrin saturation (most recent)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Transferrin saturation (3 month average)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
  • Potassium
    • Serum potassium (most recent)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum potassium (3 month average)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum potassium (peak value in 3 months)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum potassium measurement
      • Measurement in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Potassium binder use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
  • Dialysis Prescription and Dose
    • Achieved dialysis session length
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Intra-dialytic weight loss (%)
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Prescribed blood flow rate
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Prescribed dialysis sessions per week
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Prescribed dialysate potassium
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Single-pool Kt/V
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
    • Urea reduction ratio >=65%
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
    • Ultrafiltration rate
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
  • Mineral and Bone Disorder
    • IV vitamin D analog use
      • Use in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • IV vitamin D type
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Use with calcimimetics
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
    • Weekly IV vitamin D analog dose received
      • 30 day average, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 30 day average, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Oral vitamin D analog use
      • Oral vitamin D use, last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Oral vitamin D use, last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Oral vitamin D use with calcimimetics
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
    • Vitamin D analog use
      • Use in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Vitamin D type
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Route of administration
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Calcimimetics use
      • Calcimimetic use, last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Calcimimetic use, last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Calcimimetic type
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Calcimimetic use with vitamin D
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
      • Etelcalcetide use, last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Etelcalcetide use, last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum calcium (most recent)
      • Albumin-corrected, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Albumin-corrected, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Total, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Total, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum calcium (3 month average)
      • Albumin-corrected, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Albumin-corrected, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Total, categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Total, continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum phosphorus (most recent)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum phosphorus (3 month average)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Phosphate binder use
      • Use in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Phosphate binder type
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Al- or Mg-containing use in last 3 months
        • National sample
      • Fe-containing use in last 3 months
        • National sample
    • Serum PTH (most recent)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • Serum PTH (3 month average)
      • Categories
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • PTH measurement
      • Measurement in last 1 month
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
    • MBD control
      • Number of MBD markers out of range
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
      • Combinations, 2 MBD markers out of range
        • National sample
        • Hospital-based/Free-standing
        • Race (Black/non-Black)
        • Incident (<90d)/prevalent (90+d)
  • Nutrition
    • Serum albumin (most recent), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Serum albumin (most recent), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Serum albumin (3 month average), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Serum albumin (3 month average), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (most recent), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (most recent), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (3 month average), categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (3 month average), continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Normalized PCR, categories
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
    • Normalized PCR, continuous
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
  • Vascular Access
    • Vascular access in use
      • National sample
      • Hospital-based/Free-standing
      • Race (Black/non-Black)
      • Incident (<90d)/prevalent (90+d)
Download Quality of Life Data
Browse Graphics

Share





Sign up here to receive communications from DOPPS
Copyright © 2023, Arbor Research Collaborative for Health.  |  Citation Advice  |  Privacy Policy  |  Feedback?

Citation Advice

We welcome you to use the data and graphics displayed on this website. We value the distribution of knowledge for the benefit of patient care and renal research. Please use the following citation as applicable: [Title/description of webpage]. The DOPPS Practice Monitor. [URL/Address of webpage being cited]. Accessed [insert date here]. Modifying DOPPS Practice Monitor data, tables, or graphics in any form is not permitted without prior approval from the DOPPS coordinating center staff at Arbor Research. You may contact us at DOPPS@ArborResearch.org

Quality of Life Data Download

Complete the form below to download a spreadsheet of patient-reported quality of life summary data and graphs from the DPM sample